Board tracked Radar started tracking this company’s job board (6 open jobs at last check). source ↗
Trial start Phase 3: An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) source ↗
Trial start Phase 3: An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) source ↗
Trial start Phase 3: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic source ↗
Trial start Phase 1: A Study of ANX009 in Adult Participants With Lupus Nephritis source ↗
Trial start Phase 1: Dose Study of ANX1502 in Healthy Volunteers source ↗
Trial start Phase 1: Single Ascending Dose Study of ANX105 source ↗
Trial start Phase 2: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) source ↗
Trial start Phase 2: A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy source ↗
Trial start Phase 2: Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) source ↗
Trial start Phase 3: Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome source ↗
Trial start Phase 1: A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) source ↗
Trial start Phase 2: An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease source ↗
Trial start Phase 1: A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) source ↗
Trial start Phase 1: Study of ANX007 in Participants With Primary Open-angle Glaucoma source ↗
Trial start Phase 1: Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma source ↗
Trial start Phase 1: Single Dose Study of ANX005 in Healthy Volunteers source ↗
Upcoming milestones
Dec 31, 2026 (ESTIMATED) · Phase 3 · An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) · NCT07020819
Jul 31, 2027 (ESTIMATED) · Phase 3 · A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy · NCT06510816
Jul 31, 2029 (ESTIMATED) · Phase 3 · An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) · NCT07807969
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
